Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 7/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | STAT6 | P42226 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6935271 | 1.00 | PYGL (0.41) | PYGLKDM4EGMNNLMNAMAPT | |
| SCHEMBL10666441 | 1.00 | PYGL (0.41) | PYGLKDM4EGMNNLMNAMAPT | |
| SCHEMBL3664019 | 1.00 | PYGL (0.41) | PYGLKDM4EGMNNLMNAMAPT | |
| SCHEMBL3727543 | 1.00 | PYGL (0.41) | PYGLKDM4EGMNNLMNAMAPT | |
| SCHEMBL17364274 | 1.00 | PYGL (0.41) | PYGLKDM4EGMNNLMNAMAPT | |
| SCHEMBL2914676 | 1.00 | PYGL (0.41) | PYGLKDM4EGMNNLMNAMAPT | |
| SCHEMBL9855003 | 0.85 | MEN1 (0.30) | MEN1KMT2A | |
| SCHEMBL7170419 | 0.81 | ADK (0.33) | — | |
| SCHEMBL8591500 | 0.79 | PYGL (0.43) | PYGLKDM4EGMNNLMNAMAPT | |
| SCHEMBL11288786 | 0.79 | PYGL (0.43) | PYGLKDM4EGMNNLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229772-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | Univerzita Palackého v Olomouci (CZ) | 2017-10-18 | — | — | EP | claimed |
| EP-3229771-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | Univerzita Palackého v Olomouci (CZ) | 2017-10-18 | — | — | EP | claimed |
| WO-2016091235-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2016-06-16 | — | — | WO | claimed |
| WO-2016091236-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2016-06-16 | — | — | WO | claimed |
| CN-110615818-B | Synthesis method of fludarabine and nelarabine | 江西科技师范大学 | 2023-02-17 | — | — | CN | disclosed |
| US-10550144-B2 | 6-aryl-9-glycosylpurines and use thereof | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2020-02-04 | — | — | US | disclosed |
| CN-110615818-A | Synthesis method of fludarabine and nelarabine | 江西科技师范大学 | 2019-12-27 | — | — | CN | disclosed |
| US-10100077-B2 | 6-aryl-9-glycosylpurines and use thereof | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2018-10-16 | — | — | US | disclosed |
| US-20170334943-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2017-11-23 | — | — | US | disclosed |
| US-20170326168-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2017-11-16 | — | — | US | disclosed |
| EP-3229772-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | Univerzita Palackého v Olomouci (CZ) | 2017-10-18 | — | — | EP | disclosed |
| EP-3229771-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | Univerzita Palackého v Olomouci (CZ) | 2017-10-18 | — | — | EP | disclosed |
| US-20060100167-A1 | Methods and compositions for the treatment of autoimmune disorders using clofarabine | WOOD CHRISTOPHER B | 2006-05-11 | — | — | US | disclosed |
| EP-1549141-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS USING CLOFARABINE | Bioenvision, Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| EP-1478322-A2 | Beta-2'-OR 3'-HALONUCLEOSIDES | Pharmasset Limited (BB) | 2004-11-24 | — | — | EP | disclosed |
| WO-2004029025-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS USING CLOFARABINE | BIOENVISION, INC. (US) | 2004-04-08 | — | — | WO | disclosed |
| WO-2004012746-A2 | NEW USES FOR INHIBITORS OF INOSINE MONOPHOSPHATE DEHYDROGENASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-02-12 | — | — | WO | disclosed |
| WO-2003000200-A2 | β-2'-OR 3'-HALONUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-01-03 | — | — | WO | disclosed |
| WO-2002077002-A2 | SYNTHESIS OF SELENIUM-DERIVATIZED NUCLEOSIDES, NUCLEOTIDES, PHOSPHORAMIDITES, TRIPHOSPHATES AND NUCLEIC ACIDS | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2002-10-03 | — | — | WO | disclosed |
| US-4112221-A | HEATING A 2',3'-O-SULFINYL-8-OXYPURINE | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100167-A1 | Methods and compositions for the treatment of autoimmune disorders using clofarabine | TPMT, FAH, IL2 | PYGL 1297/4885KDM4E 2174/4885GMNN 1953/4885 |
| US-20170326168-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | GART, DAO, GLA | PYGL 848/4885KDM4E 1565/4885GMNN 99/4885 |
| US-10550144-B2 | 6-aryl-9-glycosylpurines and use thereof | GART, DAO, GLA | PYGL 848/4885KDM4E 1565/4885GMNN 99/4885 |
| US-20170334943-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNG, FUT6, GART | PYGL 430/4885KDM4E 2569/4885GMNN 302/4885 |
| US-10100077-B2 | 6-aryl-9-glycosylpurines and use thereof | UNG, FUT6, GART | PYGL 430/4885KDM4E 2569/4885GMNN 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.